Targeting the KCa3.1 channel suppresses diabetes-associated atherosclerosis via the STAT3/CD36 axis-Reference-Cited by-同舟云学术

Targeting the KCa3.1 channel suppresses diabetes-associated atherosclerosis via the STAT3/CD36 axis

Published:2022-03 Issue: Volume:185 Page:109776
ISSN:0168-8227
Container-title:Diabetes Research and Clinical Practice
language:en
Short-container-title:Diabetes Research and Clinical Practice

Author:

Jiang Xiao-Xin,Bian Weikang,Zhu Yan-Rong,Wang Zhicheng,Ye Peng,Gu Yue,Zhang Hongsong,Zuo Guangfeng,Li Xiaobo,Zhu Linlin,Liu Zhizhong,Sun Chongxiu,Chen Shao-Liang,Zhang Dai-Min

Funder

Jiangsu Provincial Key Research and Development Program

Publisher

Elsevier BV

Subject

Endocrinology,General Medicine,Endocrinology, Diabetes and Metabolism,Internal Medicine

Reference41 articles.

1. Epidemiology of Atherosclerosis and the Potential to Reduce the Global Burden of Atherothrombotic Disease;Herrington;Circ Res,2016

2. Mechanisms of diabetic complications;Forbes;Physiol Rev,2013

3. Macrophages in atherosclerosis: a dynamic balance;Moore;Nat Rev Immunol,2013

4. Critical regulation of atherosclerosis by the KCa3.1 channel and the retargeting of this therapeutic target in in-stent neoatherosclerosis;Zhu;J Mol Med (Berl),2019

5. Myeloid-Specific Deletion of Epsins 1 and 2 Reduces Atherosclerosis by Preventing LRP-1 Downregulation;Brophy;Circ Res,2019

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Equisetin protects from atherosclerosis in vivo by binding to STAT3 and inhibiting its activity;Pharmacological Research;2024-08

2. M2 macrophage‑derived exosomes alleviate KCa3.1 channel expression in rapidly paced HL‑1 myocytes via the NF‑κB (p65)/STAT3 signaling pathway;Molecular Medicine Reports;2024-02-08

3. Is the suppression of CD36 a promising way for atherosclerosis therapy?;Biochemical Pharmacology;2024-01

4. The role of macrophage ion channels in the progression of atherosclerosis;Frontiers in Immunology;2023-07-31

5. Endothelial KCa channels: Novel targets to reduce atherosclerosis-driven vascular dysfunction;Frontiers in Pharmacology;2023-03-31